Cyclophosphamide 500 mg
Indonesia • Ferron Par Pharmaceuticals
Indication
For carcinoma and sarcoma:
Leukemia, lymphogranulomatosis, lymphosarcomas, retothelial sarcoma, multiple myeloma, mammary carcinoma, and ovarian carcinoma.
Composition
Cyclophosphamide monohydrate 500 mg
Package
Dosage Forms
Powder for InjectionATC Classification
Warning
Dosage
0 to 18 Years Old
For continous treatment in adults and children:
3-6 mg/kg body weight daily (equivalent to 120-240 mg/m² body surface).
18 Years Old and Above
For continous treatment in adults and children:
3-6 mg/kg body weight daily (equivalent to 120-240 mg/m² body surface).
For intermittent treatment:
10-15 mg/kg body weight (equivalent to 400-600 mg/m² body surface) at intervals of 2-5 days.
For high dose intermittent treatment:
20-40 mg/kg body weight (equivalent to 800-1600 mg/m² body surface) and higher doses (e.g. for conditioning prior to bone marrow transplantation) at intervals of 21-28 days.
Administration
Cyclophosphamide monohydrate should only be administered by experienced oncologists. The dosage must be adapted to each patient individually.
Duration of therapy and intervals will depend on the indication, the applied combination chemotheraphy schedule and the patient’s general state of health, the laboratory parameters and the recovery of blood cell counts.
Attention should be paid to adequate hydration as well as to the administration of the uroprotector.
Patients with Hepatic and Renal Insufficiency
Severe hepatic or renal insufficiency requires a dose reduction. A dose reduction 25% for serum bilirubin from 3.1-5 mg/100 ml and of 50% for a glomerular filtration rate below 10 ml/minute is recommended.